CUV clinuvel pharmaceuticals limited

Ann: Preliminary results from SCENESSE adolescent EPP study, page-8

  1. 1,127 Posts.
    lightbulb Created with Sketch. 1676

    More great news from Clinuvel. The only company treating children suffering this terrible disease, and all of the eligible children in this study are requesting further treatment via special access schemes in a solid tick of approval of efficacy. And again the very safe profile of the drug is reinforced. Near term catalysts now are potential for EMA to move to 6 implants p.a. up from 3 or 4, children 12-17 treatment label extension filing 2H this year, financial growth in 2 weeks, Canada Filing, Argentina and South American possibilities, AAD meeting in less than one month, blockbuster Vitiligo Phase 3 recruitment completion and potential FDA filing next year, Ozempic potential real tanning, protective, unique transdermal photo cosmetic coming next year according to bulletin.

    Apparently according to shorters Clinuvel is going broke and has no growth potential at all as they are controlling the market totally every day with 3.6 Million shares now requiring to be bought back. The latest single day ASIC data is available (last Tuesday) shows another 20000 fake shares on that single day alone. 35000 fake Sell shares the day before that and since the share buyback was announced 11 months ago shorts have pumped in about 1.1 Million fake Sell shares. Since Sep 2023 on the back of incredible growth in profits and EPS at Clinuvel the open shorts have pumped in an absolutely amazing nearly 2.2 Million fake Sell shares in just 18 months. There are only 50 Million CUV shares on issue, most are tightly held, institutions have added millions of shares in recent years according to the Chairman, and the 2 latest annual reports show the comparison of major holders of over 5000 shares increasing in number. No one can predict a hedge fund would launch a sustained short attack on Clinuvel when they are consistently growing profits and EPS at a very solid rate. They are now in the best position they have ever been in with analysts putting price targets far in excess of the current price ($39.20 by Jefferies just weeks ago) however shorters are pumping in tremendous amounts of fake Sell liquidity to maintain their artificial undervaluation here, no one can say without those tens of thousands of fake shares every day , and millions over recent years, that the share price would not be far higher. Is it for a takeover of such a cash printing and rich company well only time will tell? $1 Million profit before tax every week for a small biotech running a blockbuster Phase 3 (plus all the rest) is not something I have ever heard of before and even with a 300% or 400% premium they would still enhance the financial metrics of most highly valued Biotechs. For a growing company a P/E approaching 10 (after taking out cash) is getting pretty ridiculous.

    All IMO DYOR


    Last edited by Silverchair: 10/02/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$9.76
Change
-0.050(0.51%)
Mkt cap ! $489.2M
Open High Low Value Volume
$9.90 $10.00 $9.76 $618.8K 62.64K

Buyers (Bids)

No. Vol. Price($)
1 195 $9.76
 

Sellers (Offers)

Price($) Vol. No.
$9.89 351 1
View Market Depth
Last trade - 16.10pm 17/06/2025 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.